SCHEMBL8237398

SCHEMBL8237398

CCC(=O)c1ccc2ccccc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.61
ALDH1A1 P00352 4/20 0.59
MAPT P10636 4/20 0.59
GAA P10253 1/20 0.59
CNR2 P34972 5/20 0.56
HDAC8 Q9BY41 1/20 0.56
KDM4C Q9H3R0 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
KDM4E B2RXH2 3/20 0.53
HPGD P15428 2/20 0.53
RAB9A P51151 4/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
LMNA P02545 2/20 0.50
NPC1 O15118 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30417045 1.00 MGAM (0.61) MGAMALDH1A1MAPTGAACNR2
SCHEMBL28665600 0.86 MGAM (0.58) MGAMALDH1A1MAPTGAACNR2
SCHEMBL8906407 0.85 ALDH1A1 (0.55) MGAMALDH1A1MAPTGAACNR2
SCHEMBL29456863 0.83 MAPT (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL27668767 0.83 MAPT (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL9664008 0.82 ALDH1A1 (0.60) MGAMALDH1A1MAPTGAACNR2
SCHEMBL14392711 0.81 MGAM (0.61) MGAMALDH1A1MAPTGAACNR2
SCHEMBL17035499 0.81 MAPT (0.64) MGAMALDH1A1MAPTGAACNR2
SCHEMBL2400093 0.81 MGAM (0.61) MGAMALDH1A1MAPTGAACNR2
SCHEMBL1459295 0.81 MGAM (0.61) MGAMALDH1A1MAPTGAACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11059799-B2 Process for preparation of eribulin and intermediates thereof DR. REDDY'S LABORATORIES LIMITED. (IN) 2021-07-13 US disclosed
CN-105884743-B Metal enzyme inhibitor compound 威尔金制药(NC)有限公司 2019-08-06 CN disclosed
CN-109400594-A Metal enzyme inhibitor compound 威尔金制药(NC)有限公司 2019-03-01 CN disclosed
CN-103781775-B Metal enzyme inhibitor compound 威尔金制药有限公司 2016-11-16 CN disclosed
WO-2016172631-A2 SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-10-27 WO disclosed
CN-105884743-A Metalloenzyme inhibitor compounds 威尔金制药有限公司 2016-08-24 CN disclosed
CN-103957908-A Substituted aminothiazoles as inhibitors of cancer including hepatocellular carcinoma and as inhibitors of hepatitis virus replication INST HEPATITIS & VIRUS RES 2014-07-30 CN disclosed
US-20120225903-A1 Novel 2-Substituted Quinoline Derivatives, And Method For Preparing Same ALPHA CHIMICA (FR) 2012-09-06 US disclosed
US-20120225903-A1 Novel 2-Substituted Quinoline Derivatives, And Method For Preparing Same ALPHA CHIMICA (FR) 2012-09-06 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
WO-2009150318-A1 NOVEL 2-SUBSTITUTED QUINOLINE DERIVATIVES, AND METHOD FOR PREPARING SAME INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) 2009-12-17 WO disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
WO-2007071738-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11059799-B2 Process for preparation of eribulin and intermediates thereof ERLIN1, ERLIN2, MAN1B1 MGAM 3733/4885ALDH1A1 1325/4885MAPT 3504/4885
US-20120225903-A1 Novel 2-Substituted Quinoline Derivatives, And Method For Preparing Same THPO, QARS1, QTRT2 MGAM 2793/4885ALDH1A1 3343/4885MAPT 3157/4885
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 MGAM 288/4885ALDH1A1 363/4885MAPT 2735/4885
US-20110046157-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 MGAM 3939/4885ALDH1A1 1220/4885MAPT 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.